ScripStock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri
ScripBiopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte
ScripSouth Korean pharma firms reported mixed third-quarter results amid a variety of operational factors, with continued solid performances from Hanmi Pharmaceutical Co., Ltd. and Daewoong Pharmaceutic
ScripKorean pharma firms reported mixed earnings for the second quarter ended 30 June, with sales growth led by in-house new drugs, prescription businesses and the generally strong performances of overseas